Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions

International Immunopharmacology

Volumn 23, Issue 2, 2014, Pages 442-446

  Bichuetti Silva, Danielli C ^a   Furlan, Fernanda P ^a   Nobre, Fernanda A ^a   Pereira, Camila T M ^a   Gonçalves, Tessa R T ^a   Gouveia Pereira, Mariana ^a   Rota, Rafael ^a   Tavares, Lusinete ^a   Mazzucchelli, Juliana T L ^a   Costa Carvalho, Beatriz T ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adverse reactions; Antibody; Infusion related; Intravenous immunoglobulin; Primary immunodeficiency

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; ATAXIA TELANGIECTASIA; BLOOM SYNDROME; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; COMBINED IMMUNODEFICIENCY; DIGEORGE SYNDROME; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HEADACHE; HUMAN; HYPER IGE SYNDROME; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INFANT; INFECTION; INFUSION RATE; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; SEIZURE; STEROID THERAPY; SUBSTITUTION THERAPY; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA; IMMUNOLOGIC DEFICIENCY SYNDROMES; MIDDLE AGED; PRESCHOOL CHILD; RISK; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; YOUNG ADULT;

EID: 84912129477     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.09.015     Document Type: Article

References (44)

1. S.V. Kaveri, M.S. Maddur, P. Hegde, S. Lacroix-Desmazes, and J. Bayry Intravenous immunoglobulin in immunodeficiencies: more than mere replacement therapy Clin Exp Immunol 164 2 2011 2 5
2. R.J. Looney, and J. Huggins Use of intravenous immunoglobulin G (IVIG) Best Pract Res Clin Haematol 19 2006 3 25
3. R.A. Sacher, and the IVIG Advisory Panel Intravenous immunoglobulin consensus statement J Allergy Clin Immunol 108 2001 139 146
4. M. Ballow Intravenous immunoglobulins: clinical experience and viral safety J Am Pharm Assoc 42 2002 449 458
5. M.B. Fasano Risks and benefits of intravenous immunoglobulin treatment in children Curr Opin Pediatr 7 1995 688 694
6. S. Skull, and A. Kemp Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93 Arch Dis Child 74 1996 527 530
7. V.M. Brennan, S. Cochrane, C. Fletcher, D. Hendy, and P. Powell Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home J Clin Immunol 15 1995 116 119
8. B. Pautard, E. Hachulla, M. Bagot d'Arc, and L. Chantreuil Intravenous immunoglobulin (Endobulin) clinical tolerance: prospective therapeutic follow-up of 142 adults and children Rev Med Interne 24 2003 505 513
9. A.M. Al Wahadneh, I.A. Khriesat, and E.H. Kuda Adverse reactions of intravenous immunoglobulin Saudi Med J 21 2000 953 956
10. M. Benesh, R. Kerbl, H. Lackner, A. Berghold, W. Schwinger, and K. Triebl-Roth Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-centre trial J Pediatr Hematol Oncol 25 2003 797 800
11. S. Dashti-Kahavidaki, A. Aghamohammadi, F. Farshadi, M. Movahedi, N. Parvaneh, and N. Pouladi Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases J Investig Allergol Clin Immunol 19 2 2009 139 145
12. R.L. Wasserman, J. Church, M. Stein, J. Moy, M. White, and S. Strausbaugh Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency J Clin Immunol 32 2012 663 669
13. U. Katz, A. Achiron, Y. Shere, and Y. Shoenfeld Safety of intravenous immunoglobulin (IVIG) therapy Autoimmun Rev 6 2007 257 259
14. E.R. Stiehm Adverse effects of human immunoglobulin therapy Transfus Med Rev 27 2013 171 178
15. B.T. Costa-Carvalho, D. Solé, A. Condino-Neto, and N. Rosário Filho I Brazilian Consensus about use of human immunoglobulin in patients with primary immunodeficiency Brazilian Society of Allergy and Immunopathology Rev Bras Alerg Imunopatol 33 3 2010 104 116
16. J. Siegel The product: all intravenous immunoglobulins are not equivalent Pharmacotherapy 25 11 2005 78 84
17. Primary immunodeficiency diseases. Report of a WHO scientific group Clin Exp Immunol 109 1 1997 1 28
18. V.M. Brennan, N.J. Salome-Bentley, and H.M. Chapel Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin Clin Exp Immunol 133 2003 247 251
19. H. Chapel, R. Geha, and F. Rosen Primary immunodeficiency diseases: an update Clin Exp Immunol 132 2003 9 15
20. M. Wittstock, R. Benecke, and U.K. Zettl Therapy with intravenous immunoglobulins: complications and side-effects Eur Neurol 50 2003 172 175
21. L.R. Pierce, and N. Jain Risks associated with use of intravenous immunoglobulin Transfus Med Rev 17 2003 241 251
22. M. Ballow Clinical and investigational considerations for the use of IVIG therapy Am J Health Syst Pharm 62 Suppl. 3 2005 S12 S18
23. A.J. Silvergleid, and M. Berger Intreavenous immune globulin: adverse effects. UpToDate, 2013 Available from: www.uptodate.com [Accessed February 28, 2014]
24. D. Singh-Grewal, A. Kemp, and M. Wong A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions Arch Dis Child 91 2006 651 654
25. E. Andres, F.X. Limbach, J.E. Kurtz, V. Kurtz-Illig, T. Schaeverbeke, and F. Pflumio Primary humoral immunodeficiency (late-onset common variable immunodeficiency) with antinuclear antibodies and selective immunoglobulin deficiency Am J Med 111 2001 489 491
26. C. Cunningham-Rundles, and C. Bodian Common variable immunodeficiency: clinical and immunological features of 248 patients Clin Immunol 92 1999 34 48
27. E.M. Eisenstein, and M.C. Sneller Common variable immunodeficiency: diagnosis and management Ann Allergy 73 1994 285 292 [quiz 93-4]
28. R. de Albuquerque Campos, M.N. Sato, and A.J. da Silva Duarte IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy J Clin Immunol 20 2000 77 82
29. M. Stangel, R. Kiefer, M. Pette, M.N. Smolka, P. Marx, and R. Gold Side effects of intravenous immunoglobulins in neurological autoimmune disorders - a prospective study J Neurol 250 2003 818 821
30. M. Berger, and P.J. Pinciaro Flebogamma 5% Investigators. Safety, efficacy and pharmacokinetics of Flebogamma 5% for replacement therapy in primary immunodeficiency diseases J Clin Immunol 24 2004 389 396
31. D.G. Vieira, B.T. Costa-Carvalho, R. Silva, S. HIX, and R.O.S. Sarni Evaluation of lipid profile and apolipoprotein A-T: relationship with enzymes associated with cardiovascular risk in patients with hypogammaglobulinaemia 2014 CIS annual meeting: Primary Immune Deficiency Diseases North American Conference 2014 Journal of Clinical Immunology 34 2014 357
32. E.C.S. Valente, T.L. Paulina, M.N. Rafael, R.O.S. Sarni, B.T. Costa-Carvalho, and R. Silva Nutricional status and food intake of patients with common variable immunodeficiency Rev Bras Nutr Clin 28 2 2013 136 141
33. M. Lucas, M. Lee, J. Lortan, E. Lopez-Granados, S. Misbah, and H. Chapel Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years J Allergy Clin Immunol 125 6 2010 1354 1360
34. M. Berger Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency Immunol Allergy Clin North Am 28 2008 413 437
35. IDF Immune Deficiency Foundation patient survey 2002 Available from: http://www.primaryimmune.org [Accessed January 20, 2014]
36. J.S. Orange, E.M. Hossny, C.R. Weiler, M. Ballow, M. Berger, and F.A. Bonilla Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology J Allergy Clin Immunol 117 4 2006 525 553
37. A. Fasth European Society for Immune Deficiency October 2006 [Budapest, Hungary] - Oral Presentation
38. E.W. Gelfand, and J. Winkelstein Are all IGIVs the same? J Allergy Clin Immunol 110 2002 938
39. L. Feldemeyer, C. Benden, S.R. Haile, A. Boehler, R. Speich, and L.E. French Not all intravenous immunoglobulin preparations are equally well tolerated Acta Derm Venereol 90 2010 494 497
40. H. Orbach, U. Katz, Y. Sherer, and Y. Shoenfeld Intravenous immunoglobulin. Adverse effects and safe administration Clin Rev Allergy Immunol 29 2006 173 184
41. F.A. Bonilla Intravenous immunoglobulin: adverse reactions and management J Allergy Clin Immunol 122 2008 1238 1239
42. H.W. Shroeder Jr., and C.J. Dougherty Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients Infection 40 2012 601 611
43. H.D. Ochs, M.L. Lee, S.A. Fischer, E.S. Delson, B.S. Chang, and R.J. Wedgwood Self-infusion of intravenous immunoglobulin by immunodeficient patients at home J Infect Dis 156 1987 652 654
44. U. Nicolay, P. Kiessling, M. Berger, S. Gupta, L. Yel, and C.M. Roifman Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home J Clin Immunol 26 1 2006 65 72